NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
149 trialsNCT01630733 2026-04-15
ENSPIRIT
Achieve Life Sciences
Phase 3 Completed
NCT02857400 2026-04-14
CREDO
Institut Claudius Regaud
Phase NA Completed
NCT04547634 2026-04-08
Telerehabilitation in Oncology Patients
University of Malaga
Phase NA Completed
NCT02087423 2026-04-06
ATLANTIC
AstraZeneca
Phase 2 Completed
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00720785 2026-04-01
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04050709 2026-04-01
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
Phase 1 Completed
NCT01445483 2026-03-31
Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases
National Institutes of Health Clinical Center (CC)
Completed
NCT02133222 2026-03-31
AMMAM
Centre Hospitalier Universitaire de Nice
Phase NA Completed
NCT02133625 2026-03-30
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT05068752 2026-03-30
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Completed
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT06538623 2026-03-24
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
Phase 2 Completed
NCT03725436 2026-03-16
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
NCT01606033 2026-03-13
IPSY
Centre Oscar Lambret
Phase NA Completed
NCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT05209880 2026-03-13
Advance Care Planning in the Emergency Department
Brigham and Women's Hospital
Phase NA Completed
NCT04308356 2026-03-11
ESOP
Assistance Publique - Hôpitaux de Paris
Completed
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04797390 2026-03-02
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
Tactile Medical
Phase NA Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT05564468 2026-02-27
Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer
Fred Hutchinson Cancer Center
Phase NA Completed
NCT04233567 2026-02-24
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03942497 2026-02-12
Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America
Latin American Cooperative Oncology Group
Completed
NCT03993353 2026-02-12
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Phase 2 Completed
NCT06229080 2026-02-12
SEGWAY
Next Biomedical Co., Ltd.
Phase NA Completed
NCT03775980 2026-02-11
CIEMAR
Cardiovascular and Interventional Radiological Society of Europe
Completed
NCT05648240 2026-02-10
EARDIS
Centre Hospitalier Universitaire de Nīmes
Completed
NCT02917993 2026-02-09
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 1/2 Completed
NCT02989064 2026-02-04
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
Phase 1 Completed
NCT06379880 2026-02-04
FEGALA
Centre Paul Strauss
Phase NA Completed
NCT07386639 2026-02-04
GENDER-HCC-MET
Tongji University
Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03082534 2026-01-28
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT04991480 2026-01-27
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1 Completed
NCT07363434 2026-01-23
RESONATE
Novartis
Completed
NCT05276284 2026-01-14
TEMPLE
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT04911998 2026-01-12
TavieSkin
Pierre Fabre Medicament
Completed
NCT02069730 2026-01-08
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
University Health Network, Toronto
Phase NA Completed
NCT03510104 2026-01-08
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Meryx, Inc.
Phase 1 Completed
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed